{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'AEs from the start of infusion through 60 minutes after infusion completion for the first 3 doses;', 'the monitoring period for subsequent doses may be reduced to 30 minutes after infusion', 'completion for subjects who do not experience infusion-associated events.', '9.4.6.3.2 Dose Modifications, Interruptions, and Delays', 'Following the appearance of either immediate or delayed infusion-associated events, subsequent', 'doses may be pre-treated with diphenhydramine (1 to 1.25 mg/kg IV; maximum of 50 mg),', 'ranitidine (50 mg IV), famotidine (0.5 mg/kg IV), dexamethasone (0.4 mg/kg IV; maximum of', '20 mg), and/or acetaminophen (500 mg). All subsequent infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes) period with vital signs monitored', 'every 15 minutes from the start of the infusion through 60 minutes after infusion completion.', '9.4.8', 'Masking and Unmasking', 'In order to maintain the study mask in HZNP-TEP-301, all subjects in this open-label extension', 'study will undergo the same dosing regimen of teprotumumab (10 mg/kg on Day 1 followed by', '20 mg/kg q3W for the remaining 7 infusions), regardless if they received teprotumumab or', 'placebo in HZNP-TEP-301.', '9.5.1', 'Efficacy Variables', 'Efficacy will be assessed by proptosis (measured as exophthalmos evaluation of the Clinical', 'Measures of Severity using a Hertel instrument provided by the Sponsor for consistency in', 'measurement), CAS (7-item scale), diplopia (measured as part of the Clinical Measures of', 'Severity) and Clinical Measures of Severity (including motility restriction assessments).', '9.5.1.1 Proptosis (Exophthalmos)', 'Proptosis will be measured for each eye on Day 1 and Weeks 6, 12, 18, and 24 (or PW) at EOT', 'during the Treatment Period, and at Months 7, 9, and 12 (or PWEOS) during the Follow-Up', 'Period. Measurements will be recorded on the Clinical Measures of Severity eCRF under', 'exophthalmos.', '9.5.1.2 Clinical Activity Score (CAS)', 'The CAS will be completed on Day 1 and Weeks 6, 12, 18, and 24 (or PW) at EOT during the', 'Treatment Period, and at Months 7,9, and 12 (or PWEOS) during the Follow-Up Period using', \"the 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amended CAS [Mourits et\", 'al, 1989] (Table 9.2).', '9.5.1.3 Clinical Measures of Severity', 'Based on the EUGOGO Consensus Statement [Bartalena et al, 2008; Wiersinga et al, 2006], the', 'following items will be assessed on Day 1 and Weeks 6, 12, 18, and 24 (or PW) at EOT during', 'the Treatment Period, and at Months 7, 9, and 12 (or PWEOS) during the Follow-Up Period', '(Table 9.3). Except when strictly unavoidable, the same observer should conduct each evaluation', 'of severity measure for the full duration of the study.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 21 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.2', 'Quality-of-Life Assessment', 'The GO-QoL questionnaire [C. B. Terwee et al, 1998] will be completed on Day 1 and Weeks 6,', '12, and 24 (or PWEOT) during the Treatment Period, and at Months 7 and 12 (or PWEOS)', 'during the Follow-Up Period.', '9.5.3', 'Pharmacokinetic Measurements', 'Blood samples will be collected in 5 mL serum separator tube (SST) collection tubes to', 'evaluate PK at the following time points: pre-and post-infusion on Day 1 and Weeks 3 and', '9 of the Treatment Period; single samples will also be collected at Weeks 1, 4, and 24 (but', 'not PW) of the Treatment Period. Samples will be collected, processed, and stored at', '> -70\u00b0C at the site until shipment to the central laboratory', 'will store the samples at 2-70\u00b0C until shipment to', 'for PK', 'testing (see Table 6.1).', 'Instructions for processing, handling, storing and shipping of PK samples will be detailed', 'in a laboratory manual that will be provided to each site prior to site initiation. A central', 'laboratory will be used for PK sample analysis.', '9.5.4.1.2 Documentation of Adverse Events', 'Adverse events that are ongoing at the completion of EOS visit in HZNP-TEP-301 and/or occur', 'prior to dosing on Day 1 will be considered pre-dose AEs. The TEAE reporting period begins', 'with administration of the first dose of study medication on Day 1 and continues until 3 weeks', 'after the last dose of study drug, and the Follow-Up AE reporting period begins 3 weeks after the', 'last dose of study drug through completion of the Follow-Up Period (Month 12 or PWEOS). All', 'pre-dose AEs, TEAEs, and AEs during the Follow-Up Period must be recorded in the source', \"documents and in the subject's eCRF.\", '9.5.4.3 Vital Signs', 'Vital signs (heart rate, blood pressure, respiratory rate, temperature) will be measured at', 'all clinic visits. Vital signs will be measured pre- and post-infusion on Day 1 and Week 3,', 'and predose on any other infusion day. In addition, if immediate infusion-associated events', 'are noted during the infusion, vital signs will be monitored every 5 minutes until stable and', 'then every 15 minutes for 2 additional determinations. Also, vital signs will be monitored', 'every 15 minutes from the start of the infusion through 60 minutes after infusion', 'completion for any subsequent infusions after the previous occurrence of immediate or', 'delayed infusion-associated events.', \"Blood pressure and pulse measurements will be obtained with the subject's arm\", 'unconstrained by clothing or other material and while the subject is sitting up. When', 'possible, the same arm will be used for measurements in all study visits. Temperature will be', 'obtained orally or via the ear.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 22 of 118']\n\n###\n\n", "completion": "END"}